JPWO2020200880A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020200880A5 JPWO2020200880A5 JP2021557758A JP2021557758A JPWO2020200880A5 JP WO2020200880 A5 JPWO2020200880 A5 JP WO2020200880A5 JP 2021557758 A JP2021557758 A JP 2021557758A JP 2021557758 A JP2021557758 A JP 2021557758A JP WO2020200880 A5 JPWO2020200880 A5 JP WO2020200880A5
- Authority
- JP
- Japan
- Prior art keywords
- residue
- val
- cit
- gly
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000005647 linker group Chemical group 0.000 claims 5
- 108010016626 Dipeptides Proteins 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- 125000004976 cyclobutylene group Chemical group 0.000 claims 2
- 125000004980 cyclopropylene group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- -1 indolizino[1,2-b]quinolin-4-yl Chemical group 0.000 claims 1
- UWVXWJCYPPLTLR-UHFFFAOYSA-N indolizino[1,2-b]quinoline Chemical compound C1=CC=CN2C=C(C=C3C(C=CC=C3)=N3)C3=C21 UWVXWJCYPPLTLR-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023002495A JP7680658B2 (ja) | 2019-03-29 | 2023-01-11 | 化合物及びその複合体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826393P | 2019-03-29 | 2019-03-29 | |
| US62/826,393 | 2019-03-29 | ||
| US202062964177P | 2020-01-22 | 2020-01-22 | |
| US62/964,177 | 2020-01-22 | ||
| PCT/EP2020/057984 WO2020200880A1 (en) | 2019-03-29 | 2020-03-23 | Compounds and conjugates thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023002495A Division JP7680658B2 (ja) | 2019-03-29 | 2023-01-11 | 化合物及びその複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022528851A JP2022528851A (ja) | 2022-06-16 |
| JPWO2020200880A5 true JPWO2020200880A5 (enExample) | 2022-08-24 |
| JP7210770B2 JP7210770B2 (ja) | 2023-01-23 |
Family
ID=69960637
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557758A Active JP7210770B2 (ja) | 2019-03-29 | 2020-03-23 | 化合物及びその複合体 |
| JP2023002495A Active JP7680658B2 (ja) | 2019-03-29 | 2023-01-11 | 化合物及びその複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023002495A Active JP7680658B2 (ja) | 2019-03-29 | 2023-01-11 | 化合物及びその複合体 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20200306243A1 (enExample) |
| EP (2) | EP4176904A1 (enExample) |
| JP (2) | JP7210770B2 (enExample) |
| KR (3) | KR102679892B1 (enExample) |
| CN (4) | CN118221763A (enExample) |
| AU (1) | AU2020252034B2 (enExample) |
| BR (1) | BR112021018986A2 (enExample) |
| CA (1) | CA3133757A1 (enExample) |
| CL (1) | CL2021002498A1 (enExample) |
| CO (1) | CO2021014566A2 (enExample) |
| CR (1) | CR20210541A (enExample) |
| DK (1) | DK3946464T3 (enExample) |
| EC (1) | ECSP21078204A (enExample) |
| ES (1) | ES2930295T3 (enExample) |
| HR (1) | HRP20221280T1 (enExample) |
| HU (1) | HUE060364T2 (enExample) |
| IL (1) | IL286291B2 (enExample) |
| LT (1) | LT3946464T (enExample) |
| MX (1) | MX2021011812A (enExample) |
| PH (1) | PH12021552363A1 (enExample) |
| PL (1) | PL3946464T3 (enExample) |
| PT (1) | PT3946464T (enExample) |
| RS (1) | RS63715B1 (enExample) |
| SG (1) | SG11202110524VA (enExample) |
| SM (1) | SMT202200439T1 (enExample) |
| TW (2) | TWI886667B (enExample) |
| UA (1) | UA129129C2 (enExample) |
| WO (1) | WO2020200880A1 (enExample) |
| ZA (1) | ZA202106612B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020018975A1 (en) | 2018-07-20 | 2020-01-23 | Genentech, Inc. | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| US11493668B2 (en) * | 2018-09-26 | 2022-11-08 | Johnson & Johnson Vision Care, Inc. | Polymerizable absorbers of UV and high energy visible light |
| CA3133757A1 (en) * | 2019-03-29 | 2020-10-08 | Medimmune Limited | Compounds and conjugates thereof |
| EP3997093A1 (en) | 2019-07-10 | 2022-05-18 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
| PH12022550037A1 (en) | 2019-07-10 | 2023-04-12 | Cybrexa 3 Inc | Peptide conjugates of microtubule-targeting agents as therapeutics |
| US20230097908A1 (en) * | 2020-01-22 | 2023-03-30 | Medimmune Limited | Compounds and conjugates thereof |
| TW202140076A (zh) * | 2020-01-22 | 2021-11-01 | 英商梅迪繆思有限公司 | 化合物及其軛合物 |
| EP4628165A2 (en) * | 2021-02-05 | 2025-10-08 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Camptothecin compound, preparation method therefor, and application thereof |
| CN115703712A (zh) | 2021-08-17 | 2023-02-17 | 江苏迈威康新药研发有限公司 | 5,8-二氨基-3,4-二氢-2h-1-萘酮的合成方法以及其中采用的中间体化合物 |
| CN116813631A (zh) * | 2021-12-16 | 2023-09-29 | 迈威(上海)生物科技股份有限公司 | 一种喜树碱类化合物及其偶联物 |
| TW202348252A (zh) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | 用治療性結合分子治療癌症的組合療法 |
| CR20240415A (es) | 2022-03-09 | 2024-11-07 | Astrazeneca Ab | MOLÉCULAS DE UNIÓN CONTRA FRa |
| AU2023229967A1 (en) | 2022-03-11 | 2024-08-08 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
| JP2025510678A (ja) | 2022-03-23 | 2025-04-15 | シンアフィックス ビー．ブイ． | カルシノエンビロニック抗原を発現する腫瘍を標的化するための抗体コンジュゲート |
| AU2023241225A1 (en) | 2022-03-23 | 2024-08-29 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
| WO2023180490A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
| CN120826241A (zh) | 2022-03-23 | 2025-10-21 | 新锐生物技术公司 | 用于靶向表达ptk7的肿瘤的抗体缀合物 |
| CA3245602A1 (en) | 2022-03-25 | 2023-09-28 | Zymeworks Bc Inc | ANTIBODY-DRUG CONJUGATIONS TARGETING THE ALPHA FOLATE RECEPTOR AND METHODS OF USE |
| CN115160403B (zh) * | 2022-07-05 | 2025-06-27 | 博石丰生命科技(南通)有限公司 | 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法 |
| KR20250148670A (ko) | 2023-02-16 | 2025-10-14 | 아스트라제네카 아베 | 치료용 결합 분자를 사용한 암 치료를 위한 병용 요법 |
| WO2024223899A1 (en) | 2023-04-28 | 2024-10-31 | Medimmune Limited | B7-h4 therapeutic binding molecules for the treatment of cancer |
| TW202508638A (zh) * | 2023-05-12 | 2025-03-01 | 大陸商百奧賽圖(北京)醫藥科技股份有限公司 | 連結子化合物及配體－藥物接合物、其製備方法及用途 |
| US20250051463A1 (en) | 2023-07-31 | 2025-02-13 | Astrazeneca Ab | Cd123 antibody-drug conjugates and methods of using the same |
| WO2025103192A1 (zh) * | 2023-11-16 | 2025-05-22 | 上海齐鲁制药研究中心有限公司 | 一种氘代喜树碱化合物及其制备和应用 |
| WO2025167742A1 (zh) * | 2024-02-06 | 2025-08-14 | 四川科伦博泰生物医药股份有限公司 | 抗体药物偶联物及其制备方法和用途 |
| WO2025167743A1 (zh) * | 2024-02-06 | 2025-08-14 | 四川科伦博泰生物医药股份有限公司 | 抗体药物偶联物及其制备方法和用途 |
| WO2025191470A1 (en) | 2024-03-12 | 2025-09-18 | Astrazeneca Ab | Processes and compounds for the preparation of topoisomerase i inhibitor linker-payloads |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4939255A (en) | 1987-06-24 | 1990-07-03 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic camptothecin derivatives |
| JP2754022B2 (ja) * | 1988-11-18 | 1998-05-20 | 第一製薬株式会社 | カンプトテシン類縁体 |
| JP3024013B2 (ja) * | 1990-08-14 | 2000-03-21 | 杏林製薬株式会社 | フルオロエチルカンプトテシン誘導体 |
| JP3008226B2 (ja) | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| US6407115B1 (en) | 1991-01-16 | 2002-06-18 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic compound |
| US5637770A (en) | 1991-01-16 | 1997-06-10 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic compound |
| JP3359955B2 (ja) * | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
| ATE227703T1 (de) | 1995-02-22 | 2002-11-15 | Daiichi Seiyaku Co | Aminotetralon-derivate und verfahren zu deren herstellung |
| US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
| US5663177A (en) | 1995-05-31 | 1997-09-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs |
| JPH1095802A (ja) * | 1995-12-28 | 1998-04-14 | Tanabe Seiyaku Co Ltd | カンプトテシン誘導体 |
| IN189180B (enExample) | 1997-07-09 | 2003-01-04 | Chong Kun Dang Corp | |
| AR030207A1 (es) | 2000-04-07 | 2003-08-13 | Daiichi Seiyaku Co | Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma |
| US6403604B1 (en) * | 2001-03-01 | 2002-06-11 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
| EP1295864B1 (en) | 2001-05-08 | 2008-12-03 | Mitsui Chemicals Polyurethanes, Inc. | Process for preparation of 1,5-diaminonaphthalenes |
| ATE398131T1 (de) | 2001-11-30 | 2008-07-15 | Chugai Pharmaceutical Co Ltd | Kondensierte camptothecine als antitumormittel |
| CN1777611A (zh) | 2003-02-21 | 2006-05-24 | 中外制药株式会社 | 制备六环喜树碱衍生物的方法 |
| JP4823894B2 (ja) | 2004-04-09 | 2011-11-24 | 中外製薬株式会社 | 新規水溶性プロドラッグ |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| EP1934174B1 (en) | 2005-10-07 | 2011-04-06 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| DK1813614T3 (da) | 2006-01-25 | 2012-01-23 | Sanofi Sa | Cytotoksiske midler, der omfatter nye tomaymycinderivater |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| MY188455A (en) | 2007-10-19 | 2021-12-09 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| CN102076717B (zh) | 2008-04-30 | 2016-02-03 | 伊缪诺金公司 | 交联剂和它们的用途 |
| WO2012096832A2 (en) * | 2011-01-12 | 2012-07-19 | Crystal Biopharmaceutical Llc | Hdac inhibiting derivatives of camptothecin |
| CN102850400A (zh) * | 2011-06-30 | 2013-01-02 | 周文强 | 喜树碱衍生物及其制备方法、药物组合物与用途 |
| KR102498405B1 (ko) | 2012-10-11 | 2023-02-09 | 다이이찌 산쿄 가부시키가이샤 | 글리신아미드 화합물의 제조 방법 |
| WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| US9962452B2 (en) * | 2013-02-04 | 2018-05-08 | Zhuhai Beihai Biotech Co., Ltd. | Soluble complexes of drug analogs and albumin |
| JP6745218B2 (ja) * | 2013-11-27 | 2020-08-26 | レッドウッド バイオサイエンス， インコーポレイテッド | ヒドラジニル−ピロロ化合物及び複合体を生成するための方法 |
| PT3088419T (pt) | 2013-12-25 | 2019-01-11 | Daiichi Sankyo Co Ltd | Conjugado de anticorpo anti-trop2-fármaco |
| CA2928794C (en) | 2014-01-31 | 2019-08-13 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-drug conjugate |
| JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| RU2711640C2 (ru) | 2014-04-10 | 2020-01-17 | Дайити Санкио Компани, Лимитед | Конъюгат анти-her3 антитело-лекарственное средство |
| WO2015155976A1 (ja) | 2014-04-10 | 2015-10-15 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| ES2740907T3 (es) | 2014-10-03 | 2020-02-07 | Synaffix Bv | Enlazador de sulfamida, conjugados de los mismos y métodos de preparación |
| ES2878023T3 (es) | 2015-01-30 | 2021-11-18 | Sutro Biopharma Inc | Derivados de hemiasterlina para conjugación y terapia |
| GB201506393D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| CN107922477B (zh) | 2015-06-29 | 2022-11-01 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| MA43354A (fr) * | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| WO2018066626A1 (ja) | 2016-10-07 | 2018-04-12 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
| TW201832778A (zh) | 2016-11-10 | 2018-09-16 | 美商麥迪紐有限責任公司 | 對ａｓｃｔ２具有特異性的結合分子及其用途 |
| US11273155B2 (en) | 2016-12-12 | 2022-03-15 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| KR102537651B1 (ko) | 2017-01-17 | 2023-05-26 | 다이이찌 산쿄 가부시키가이샤 | 항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트 |
| KR20240074000A (ko) | 2017-02-28 | 2024-05-27 | 다이이찌 산쿄 가부시키가이샤 | 항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법 |
| TW202530219A (zh) | 2017-05-15 | 2025-08-01 | 日商第一三共股份有限公司 | 抗體－藥物結合物之製造方法 |
| CN108853514B (zh) | 2017-08-18 | 2022-07-22 | 四川百利药业有限责任公司 | 具有两种不同药物的抗体药物偶联物 |
| CN109106951A (zh) | 2017-08-18 | 2019-01-01 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
| CA3133757A1 (en) * | 2019-03-29 | 2020-10-08 | Medimmune Limited | Compounds and conjugates thereof |
-
2020
- 2020-03-23 CA CA3133757A patent/CA3133757A1/en active Pending
- 2020-03-23 PH PH1/2021/552363A patent/PH12021552363A1/en unknown
- 2020-03-23 US US16/826,405 patent/US20200306243A1/en not_active Abandoned
- 2020-03-23 MX MX2021011812A patent/MX2021011812A/es unknown
- 2020-03-23 JP JP2021557758A patent/JP7210770B2/ja active Active
- 2020-03-23 AU AU2020252034A patent/AU2020252034B2/en active Active
- 2020-03-23 LT LTEPPCT/EP2020/057984T patent/LT3946464T/lt unknown
- 2020-03-23 CN CN202410334111.XA patent/CN118221763A/zh active Pending
- 2020-03-23 PL PL20713873.6T patent/PL3946464T3/pl unknown
- 2020-03-23 CN CN202410334103.5A patent/CN118240003A/zh active Pending
- 2020-03-23 KR KR1020237003605A patent/KR102679892B1/ko active Active
- 2020-03-23 CN CN202080025199.7A patent/CN113631196B/zh active Active
- 2020-03-23 DK DK20713873.6T patent/DK3946464T3/da active
- 2020-03-23 HU HUE20713873A patent/HUE060364T2/hu unknown
- 2020-03-23 KR KR1020247021308A patent/KR20240104214A/ko active Pending
- 2020-03-23 PT PT207138736T patent/PT3946464T/pt unknown
- 2020-03-23 US US17/599,374 patent/US20220211863A1/en active Pending
- 2020-03-23 HR HRP20221280TT patent/HRP20221280T1/hr unknown
- 2020-03-23 ES ES20713873T patent/ES2930295T3/es active Active
- 2020-03-23 CR CR20210541A patent/CR20210541A/es unknown
- 2020-03-23 CN CN202311084298.4A patent/CN117263948B/zh active Active
- 2020-03-23 SG SG11202110524VA patent/SG11202110524VA/en unknown
- 2020-03-23 SM SM20220439T patent/SMT202200439T1/it unknown
- 2020-03-23 UA UAA202105856A patent/UA129129C2/uk unknown
- 2020-03-23 BR BR112021018986A patent/BR112021018986A2/pt unknown
- 2020-03-23 KR KR1020217035043A patent/KR102498681B1/ko active Active
- 2020-03-23 WO PCT/EP2020/057984 patent/WO2020200880A1/en not_active Ceased
- 2020-03-23 IL IL286291A patent/IL286291B2/en unknown
- 2020-03-23 RS RS20221023A patent/RS63715B1/sr unknown
- 2020-03-23 EP EP22189090.8A patent/EP4176904A1/en active Pending
- 2020-03-23 EP EP20713873.6A patent/EP3946464B1/en active Active
- 2020-03-27 TW TW112146860A patent/TWI886667B/zh active
- 2020-03-27 TW TW109110410A patent/TWI826676B/zh active
-
2021
- 2021-06-15 US US17/348,236 patent/US11446292B2/en active Active
- 2021-09-08 ZA ZA2021/06612A patent/ZA202106612B/en unknown
- 2021-09-27 CL CL2021002498A patent/CL2021002498A1/es unknown
- 2021-10-22 EC ECSENADI202178204A patent/ECSP21078204A/es unknown
- 2021-10-28 CO CONC2021/0014566A patent/CO2021014566A2/es unknown
-
2023
- 2023-01-11 JP JP2023002495A patent/JP7680658B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020200880A5 (enExample) | ||
| JP7447183B2 (ja) | 親水性抗体－薬物コンジュゲート | |
| HRP20221280T1 (hr) | Spojevi i njihovi konjugati | |
| CA3213625A1 (en) | Selective drug release from internalized conjugates of biologically active compounds | |
| JP2025510629A (ja) | カンプトテシンコンジュゲート | |
| US20180147294A1 (en) | Antibody-drug conjugates, compositions and methods of use | |
| JP2021521111A (ja) | カンプトテシンペプチドコンジュゲート | |
| JP2023520930A (ja) | 電荷多様性リンカー | |
| US20240261422A1 (en) | Anthracycline antibody conjugates | |
| CA2988806A1 (en) | Conjugates of cysteine engineered antibodies | |
| CA3207893A1 (en) | Immunomodulatory antibody-drug conjugates | |
| JP2017537893A5 (enExample) | ||
| CA2944699A1 (en) | Affinity medicant conjugates | |
| JP2020510656A (ja) | 自己犠牲型ペプチドリンカーを有するメイタンシノイド誘導体及びそのコンジュゲート | |
| EP4642488A1 (en) | Antibody drug conjugates | |
| JP6585650B2 (ja) | 細胞毒性剤と細胞結合受容体との共役体 | |
| JPWO2021148501A5 (enExample) | ||
| US11576876B2 (en) | Affinity Medicant Conjugate | |
| JPWO2021148500A5 (enExample) | ||
| JP2025524986A (ja) | オーリスタチン誘導体およびそのコンジュゲート | |
| WO2024121632A1 (en) | Use of anti-cd117 antibody drug conjugate (adc) | |
| NZ761642B2 (en) | Hydrophilic antibody-drug conjugates | |
| NZ722252B2 (en) | Hydrophilic antibody-drug conjugates | |
| NZ761646B2 (en) | Hydrophilic antibody-drug conjugates | |
| NZ761644B2 (en) | Hydrophilic antibody-drug conjugates |